Join Our 20,000+ Subscribers. Get Weekly News Sent To Your Email
Subscribe to our newsletter and stay updated on the latest Critical Care Medicine related news.
See Past Critical Care Newsletter issues

Subscribe to Newsletter

FDA Approves Zinplava to Reduce Recurrence of Clostridium difficile Infection in Adult Patients

mercknewsroom.com October 28, 2016

FDA Approves Merck’s ZINPLAVA (bezlotoxumab) to Reduce Recurrence of Clostridium difficile Infection (CDI) in Adult Patients Receiving Antibacterial Drug Treatment for CDI Who Are at High Risk of CDI Recurrence.